Bepranemab

UCB Pharma's bepranemab, a monoclonal antibody targeting tau, shows potential in slowing tau pathology in Alzheimer's patients with low baseline tau levels and no ApoE4, suggesting a new treatment strategy. Researchers highlight tau seeding's role in disease progression, and ongoing trials aim to optimize treatment timing and population selection.

TOGETHER study showed bepranemab, an anti-tau antibody, had no effect on primary endpoint (CDR-SB) but improved cognitive outcomes (ADAS-Cog) at 80 weeks in prodromal to mild Alzheimer's disease patients.

Weekend warrior activity linked to lower dementia risk; physical activity post-dementia diagnosis reduces mortality; deferiprone worsens early Alzheimer's; bepranemab shows mixed results; LX1001 improves APOE2 and tau biomarkers; low-dose interleukin-2 safe in Alzheimer's; out-of-pocket costs for neuro drugs rise; autism diagnoses increase; Alzheimer's GWAS data criticized; NHLPA forms CTE advisory committee; debate on reporting medically impaired drivers.

Regeneron's Eylea sales miss estimates, UCB sees potential in Alzheimer's drug bepranemab, Madrigal's Rezdiffra sales exceed expectations, AbbVie partners with EvolveImmune for cancer drugs, Lundbeck acquires Longboard Pharmaceuticals, and PTC Therapeutics awaits FDA decision on Translarna for Duchenne muscular dystrophy.

UCB evaluates Alzheimer’s drug potential post Phase II miss and Roche’s departure, noting possible benefits for specific patient groups from bepranemab, despite the anti-tau candidate’s uncertain future.

Madrigal's Rezdiffra sales exceed expectations, Compass Pathways lays off 30% of staff due to delayed clinical trials, UCB's tau-targeting Alzheimer's drug bepranemab shows mixed results, and Lilly's earnings surprise discussed on 'The Readout LOUD' podcast.

UCB reported Phase 2a TOGETHER study data on bepranemab, an anti-tau antibody for Alzheimer’s disease, showing no primary endpoint benefit but significant secondary endpoint benefits in tau accumulation and cognitive decline reduction. Bepranemab was well-tolerated with an acceptable safety profile.

UCB reported Phase 2a TOGETHER study data on bepranemab, an anti-tau antibody for Alzheimer’s disease, showing no primary endpoint benefit but significant tau accumulation and cognitive decline slowing in key subgroups. Bepranemab was well-tolerated with an acceptable safety profile.

Roche ends Alzheimer’s partnership with UCB, returning rights to Phase 2a candidate bepranemab. This marks Roche's third Alzheimer’s candidate termination this year, following similar actions with AC Immune. Despite setbacks, Roche remains active in early Alzheimer’s diagnosis.